BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New B) ponatinib Sensitive : A2 EHA 2023 - 2wk	ponatinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks ponatinib Sensitive : A2 EHA 2023 - 2 weeks - (New B)
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks (New C3) blinatumomab + inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2wk	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks blinatumomab + inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2 weeks - (New C3)
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks (New C3) inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2wk	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib + blinatumomab Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) ponatinib + blinatumomab Sensitive : C3 EHA 2023 - 2wk	ponatinib + blinatumomab Sensitive: C3 – Early Trials EHA 2023 - 2 weeks ponatinib + blinatumomab Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) olverembatinib Sensitive : C3 EHA 2023 - 2wk	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks olverembatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
IKZF1 deletion	B Acute Lymphoblastic Leukemia	IKZF1 deletion	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) CD19-targeted CAR-T immunotherapy Resistant : C3 EHA 2023 - 2wk	CD19-targeted CAR-T immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks CD19-targeted CAR-T immunotherapy Resistant : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) flumatinib Sensitive : C3 EHA 2023 - 2wk	flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks flumatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) olverembatinib Sensitive : C3 EHA 2023 - 2wk	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks olverembatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3 EHA 2023 - 2wk	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	venetoclax + flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax + flumatinib Sensitive : C3 EHA 2023 - 2wk	venetoclax + flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax + flumatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
CD70 expression	B Acute Lymphoblastic Leukemia	CD70 expression	B Acute Lymphoblastic Leukemia	CD70-targeted CAR-T immunotherapy Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) CD70-targeted CAR-T immunotherapy Sensitive : D EHA 2023 - 2wk	CD70-targeted CAR-T immunotherapy Sensitive: D – Preclinical EHA 2023 - 2 weeks CD70-targeted CAR-T immunotherapy Sensitive : D EHA 2023 - 2 weeks - (New D)
KMT2A rearrangement + RAS mutation	B Acute Lymphoblastic Leukemia	KMT2A rearrangement + RAS mutation	B Acute Lymphoblastic Leukemia	selumetinib + SNDX-5613 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) selumetinib + SNDX-5613 Sensitive : D EHA 2023 - 2wk	selumetinib + SNDX-5613 Sensitive: D – Preclinical EHA 2023 - 2 weeks selumetinib + SNDX-5613 Sensitive : D EHA 2023 - 2 weeks - (New D)
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : C1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : C1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : C1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : C1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
CD20 positive	Childhood B Acute Lymphoblastic Leukemia	CD20 positive	Childhood B Acute Lymphoblastic Leukemia	rituximab Sensitive: A1 - Approval rituximab Sensitive : C1	rituximab Sensitive: A1 - Approval rituximab Sensitive : C1
PDGFRA fusion	Childhood B Acute Lymphoblastic Leukemia	PDGFRA fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
FGFR fusion	Childhood B Acute Lymphoblastic Leukemia	FGFR fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2

B Acute Lymphoblastic Leukemia

Associations(173)

Associations
(173)